NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

$13.95

-2.46 (-14.99%)

(As of 09/30/2022 09:01 PM ET)

Add

Compare

Today's Range: $12.94
▼
$14.97
50-Day Range: $12.21
▼
$19.70
52-Week Range: $10.81
▼
$21.25

Volume: 6.57 million shs
Average Volume: 958,511 shs
Market Capitalization: $415.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.55

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 76.0% Upside
$24.55 Price Target
Short Interest: Healthy
20.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.13
Upright™ Environmental Score
News Sentiment: 0.53
Based on 16 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.92) to ($3.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

231st out of 1,095 stocks

Pharmaceutical Preparations Industry

97th out of 547 stocks

4.2

Analyst's Opinion

Consensus Rating
Intercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.55, Intercept Pharmaceuticals has a forecasted upside of 76.0% from its current price of $13.95.
Amount of Analyst Coverage
Intercept Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
20.89% of the float of Intercept Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Intercept Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Intercept Pharmaceuticals has recently decreased by 9.65%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Intercept Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Intercept Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Intercept Pharmaceuticals is -2.13.

2.0

News and Social Media Coverage

News Sentiment
Intercept Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Intercept Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for ICPT on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Intercept Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.70% of the stock of Intercept Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.00% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Intercept Pharmaceuticals are expected to decrease in the coming year, from ($2.92) to ($3.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intercept Pharmaceuticals is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intercept Pharmaceuticals is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

October 2, 2022 | finance.yahoo.com

Institutional owners may take dramatic actions as Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) recent 8.5% drop adds to one-year losses

September 30, 2022 | reuters.com

Intercept Pharma's liver disease drug fails late-stage trial

September 30, 2022 | seekingalpha.com

Intercept stock slumps 18% as liver disease drug fails phase 3 trial

September 30, 2022 | marketwatch.com

Intercept Pharmaceuticals Shares Slide After NASH Study Miss >ICPT

September 30, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

September 30, 2022 | marketwatch.com

Intercept Phase 3 Compensated Cirrhosis NASH Study Misses Primary Endpoint >ICPT

September 30, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

September 26, 2022 | finance.yahoo.com

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

September 22, 2022 | markets.businessinsider.com

B.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)

September 21, 2022 | finance.yahoo.com

Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning

September 21, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

September 20, 2022 | finance.yahoo.com

Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

September 7, 2022 | finance.yahoo.com

Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

September 2, 2022 | finance.yahoo.com

Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?

August 29, 2022 | finance.yahoo.com

Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022

August 29, 2022 | finance.yahoo.com

Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options

August 23, 2022 | nasdaq.com

Noteworthy Tuesday Option Activity: ICPT, IPI, ORCL

August 22, 2022 | markets.businessinsider.com

Raymond James Maintains Outperform Rating for Intercept Pharmaceuticals: Here's What You Need To Know

August 22, 2022 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About Intercept Pharmaceuticals

August 19, 2022 | benzinga.com

Check Out What Whales Are Doing With ICPT

August 18, 2022 | finance.yahoo.com

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

August 18, 2022 | finance.yahoo.com

Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022

August 17, 2022 | seekingalpha.com

Intercept, Dr. Reddy’s settle patent dispute over Oclaiva generics

August 8, 2022 | investing.com

Intercept Pharmaceuticals PT Lowered to $16 at H.C. Wainwright

August 5, 2022 | finance.yahoo.com

Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings: 8/03/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ICPT
CUSIP: 45845P10
CIK: 1270073
Web: www.interceptpharma.com
Phone: (646) 747-1000
Fax: 646-747-1001
Employees: 437
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.55
High Stock Price Forecast: $49.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +76.0%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-91,430,000.00
Net Margins: -18.73%
Pretax Margin: -18.31%
Return on Equity: N/A
Return on Assets: -18.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.22
Quick Ratio: 3.22

Sales & Book Value

Annual Sales: $363.47 million
Price / Sales: 1.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($6.23) per share
Price / Book: -2.24

Miscellaneous

Outstanding Shares: 29,798,000
Free Float: 22,736,000
Market Cap: $415.68 million
Optionable: Optionable
Beta: 1.09

Key Executives

Mr. Jerome B. Durso (Age 54)
Pres, CEO & Director
Comp: $1.16M

Mr. Andrew Saik (Age 53)
Chief Financial Officer
Comp: $485.07k

Mr. Rocco Venezia (Age 46)
Chief Accounting Officer & Treasurer
Comp: $660.62k

Mr. Jared M. Freedberg J.D. (Age 54)
Gen. Counsel
Comp: $691.46k

Dr. M. Michelle Berrey M.D. (Age 55)
M.P.H., MPH., Pres of R&D and Chief Medical Officer
Comp: $732.13k

Mr. Nareg Sagherian
Exec. Director of Global Investor Relations

Mr. David Ford (Age 52)
Chief HR Officer

Dr. Mark Pruzanski M.D. (Age 54)
Founder, Advisor & Director

Ms. Linda M. Richardson (Age 58)
Exec. VP & Chief Commercial Officer

Paul Nitschmann
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings or view top-rated stocks.
What is Intercept Pharmaceuticals' stock price forecast for 2022?: 9 analysts have issued twelve-month price targets for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $16.00 to $49.00. On average, they expect the company's stock price to reach $24.55 in the next year. This suggests a possible upside of 76.0% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.
How have ICPT shares performed in 2022?: Intercept Pharmaceuticals' stock was trading at $16.29 on January 1st, 2022. Since then, ICPT shares have decreased by 14.4% and is now trading at $13.95.
View the best growth stocks for 2022 here.
When is Intercept Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ICPT earnings forecast.
How were Intercept Pharmaceuticals' earnings last quarter?: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.15. The biopharmaceutical company earned $100.40 million during the quarter, compared to analysts' expectations of $94.85 million.
What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?: 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).
What is Intercept Pharmaceuticals' stock symbol?: Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How do I buy shares of Intercept Pharmaceuticals?: Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intercept Pharmaceuticals' stock price today?: One share of ICPT stock can currently be purchased for approximately $13.95.
How much money does Intercept Pharmaceuticals make?: Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $415.68 million and generates $363.47 million in revenue each year. The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.
How many employees does Intercept Pharmaceuticals have?: The company employs 437 workers across the globe.
How can I contact Intercept Pharmaceuticals?: Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

Intercept Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows